Lipid Nanoparticles to Deliver miRNA in Cancer
Lipid Nanoparticles to Deliver miRNA in Cancer
复制标题
DOI：
10.2174/138920101708160517234941
复制
发表时间：
2016-01-01
影响因子：
2.8
通讯作者：
Grimaldi, Anna
中科院分区：
文献类型：
--
作者：
Campani, Virginia;De Rosa, Giuseppe;Grimaldi, Anna
MicroRNAs （miRNAs）是一类转录后基因表达调节剂。在过去的二十年里，发现了1500多种人类mirna。这些小的非编码rna调节各种生物过程，包括细胞生长、增殖、分化和细胞死亡。因此，mirna已被提出作为不同多因子疾病（如癌症）的新治疗药物。由于miRNAs治疗具有巨大的前景，许多研究都集中在开发递送策略以克服miRNAs生物制药问题。脂质传递系统由于其生物相容性、可生物降解性、易于生产、低毒性和免疫原性以及易于修饰载体以实现靶向策略的可能性，无疑是研究最多的非病毒载体。在这篇综述中，我们对目前用于递送mirna的脂质传递系统进行了快速和最新的概述，指出了在优化这些纳米载体方面取得的进展，这些进展导致了第一次临床试验。
MicroRNAs (miRNAs) are a class of post-transcriptional gene expression modulators. In the past two decades, over 1500 human miRNAs were discovered. These small non-coding RNAs regulate various biological processes, including cell growth, proliferation, differentiation, and cell death. Thus, miRNAs have been proposed as new therapeutical agents in different multifactorial diseases such as cancer. Since miRNAs therapies represent a great promise, many research studies have been focused on the development of delivery strategies to overcome miRNAs biopharmaceutical issues. Lipid delivery systems are undoubtedly the non-viral carriers most largely investigated due to their biocompatibility, biodegradability, easy production, low toxicity and immunogenicity, possibility to easily modify the carriers for targeting strategies. In this mini-review we provide a rapid and updated overview on the lipid delivery system currently used to deliver miRNAs, pointing out the progresses achieved in the optimization of these nanovectors, which led up to the first clinical trial.